Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rATG versus rATG combined with IVIG induction immunosuppression in HLA-incompatible kidney transplantation
2019-003723-37Phase 3Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Oct 2019
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in end-stage kidney disease (ESKD) comparing rATG induction with rATG + IVIG induction (2 arms). Started Oct 2019; status: completed.
02
Drugs
antithymocyte globulinpolyvalent human immunoglobulin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2019-003723-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003723-37.